BioNTech's BNT113 mRNA cancer immunotherapy misses primary progression-free survival goal in Phase 2/3 HPV16-positive head and neck cancer trial
The early efficacy check failure marks a third mRNA setback for BioNTech, though analysts note overall survival data could still support a development path.
Biopharmadive · +13 outlets
BlackRock to buy majority stake in Humana's CenterWell senior primary care clinics for $2.8 billion
The deal swaps private equity backers Welsh Carson for BlackRock at a time of rising scrutiny over Medicare-focused clinic ownership.
STAT · +14 outlets
Roche extends China deal streak with $1B pact for Rona Therapeutics RNAi obesity drug
The alliance adds to Roche's active China licensing stretch and follows a broader industry bet on medicines that lower visceral fat.
Biopharmadive · +2 outlets
FTC asks court to hold Martin Shkreli in contempt, demands he divest pharma stocks
Regulators say the move enforces a court order barring Shkreli from working in the pharmaceutical industry.
STAT · +9 outlets
Bristol Myers shares dip as admilparant lung drug results called 'confounding'
Only the lower of two tested doses met the main goal in idiopathic pulmonary fibrosis, raising analyst doubts about the therapy's prospects.
Biopharmadive · +2 outlets
FDA approves Asahi Kasei's Hovilpri for drug-resistant herpes infections in immunocompromised adults
The approval adds a new treatment option for persistent herpes lesions in immunocompromised patients.
Indian Pharma Post · +11 outlets
Analysts find many patient and consumer reps on FDA advisory panels have ties to pharma-funded groups
The analysis found that nearly 40% of FDA advisory committee meetings over 20 years included a patient or consumer rep with active ties to a pharma-funded advoc
STAT · +4 outlets
Centanafadine (Simtriyo) wins FDA approval for ADHD treatment
The clearance adds a new non-stimulant option to the ADHD treatment landscape.
ADDitude · +8 outlets
Divergent cancer vaccine trial results leave field grappling with hard questions
Mixed outcomes across mRNA and personalized vaccine studies are prompting the oncology field to reassess trial design and endpoints.
The Boston Globe · +1 outlets
Parkinson's cell therapy developer Aspen Neuroscience files for IPO
Aspen aims to raise funds on the Nasdaq for a lead program turning a patient's own cells into dopamine-producing neurons.
Biopharmadive · +7 outlets
Paragon spinout Velaris goes public via reverse merger with Alaunos and Fairmount
The deal is another example of Paragon and investor Fairmount quickly executing complicated reverse mergers.
Biopharmadive · +1 outlets
Concerns grow over safety issues tied to Neurocrine Biosciences rare disease drug
Patient advocates and some experts are raising alarm about perceived risks of the Prader-Willi treatment Vykat XR.
STAT · +8 outlets
Helen Branswell, STAT infectious disease reporter, dies at 69
Branswell earned wide respect for accessible, prescient reporting on infectious diseases and public health.
STAT · +3 outlets
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
Brent Saunders and Bausch mutually agreed on his exit, while Tezspire data offered a possible edge on Dupixent.
Biopharmadive · +2 outlets
NIH launches $200 million cancer vaccine push under Trump and Kennedy, reviving mRNA interest
The federal funding effort and reports of a U.S.-led push drove a rally in vaccine stocks.
TrialSite News · +2 outlets
Syndax shares fall as lung fibrosis drug fails trial
The trial miss sent shares lower and raises questions about the company's pipeline prospects.
pharmaphorum · +5 outlets
EMA rejects MaaT Pharma's Xervyteg approval; company shifts focus to US Phase 3 trial
The European regulator's rejection pushes MaaT toward its US development path.
scanx.trade · +1 outlets
First Tracks climbs on 'impressive' celiac study data for CD122 drug
Early findings strengthened analyst belief that the drug could have pipeline-in-a-product potential.
Biopharmadive · +1 outlets